Determination of the median effective dose of propofol in combination with different doses of esketamine during painless gastrointestinal endoscopy in adults

Status

Recruiting

Phases

Phase 4

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2100044567

Enrollment

Unknown

Registered

2021-03-24

Start date

2021-05-01

Completion date

Unknown

Last updated

2022-01-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

painless gastrointestinal endoscopy

Interventions

E0:0.9% normal saline

E1:esketamine dose: 0.15 mg/kg

E2:esketamine dose: 0.25 mg/kg

E3:esketamine dose: 0.5 mg/kg

Eligibility

Sex/Gender

All

Age

18 Years to 65 Years

Inclusion criteria

Inclusion criteria: ASA 1-3; Age 18-65 years; BMI 18.5-27.9 kg/m2; Informed Consent has been signed.

Exclusion criteria

Exclusion criteria: 1.Allergic to or have a history of allergy to any drug used in the study; 2.Preoperative use of analgesic and sedative drugs; 3.Preoperative hypertension, heart disease and other systemic diseases, intracranial pressure, intraocular pressure increased; 4.A history of alcohol abuse, serious drug abuse, and severe systemic infections; 5.Pregnant or lactating women; 6.Severe mental and neurological symptoms, such as language comprehension disorder, mental illness, etc.; 7.Participation in other clinical trials in the 3 months prior to study inclusion.

Design outcomes

Primary

Measure	Time frame
median effective concentration of propofol;	—

Countries

China

Contacts

Public ContactZhang Weiwei

Shanxi Bethune Hospital

sxbqeyyzww@163.com+86 15234121313

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026